Risks of Respiratory Syncytial Virus in Older Adults: Emerging Prophylactic Vaccines and Intervention Opportunities for Pharmacists
On-Demand Accredited Online Article featuring Animation and Patient Counseling Video Vignettes
This activity is supported by an educational grant from
Janssen Therapeutics, Division of Janssen Products, LP.
Janssen Therapeutics, Division of Janssen Products, LP.
Faculty
Miranda Wilhelm, PharmD
Clinical Professor
Southern Illinois University Edwardsville (SIUE) School of Pharmacy
Department of Pharmacy Practice
Edwardsville, Illinois
Program Description
Each year in the United States, nearly 170,000 older adults are hospitalized due to a respiratory syncytial virus (RSV) infection. RSV commonly presents as an upper respiratory infection and, in the older adult population, complications requiring hospitalization can be exacerbated by comorbid conditions, such as cardiovascular disease. Current treatment for RSV mainly includes supportive care; however, in the absence of effective treatment options, there is an urgent need for pharmacists to educate the older adult population about RSV prevention strategies to reduce RSV-associated morbidity and mortality. Fortunately, several RSV vaccine candidates have been developed and are in clinical trials. These vaccine candidates are in various stages of development, but could offer a potential method to help minimize the burden of RSV in vulnerable populations. This activity features counseling vignettes that will aid pharmacists with identifying populations with risk factors for RSV infection, review strategies to promote awareness of the severity of RSV, and facilitate patient education regarding the importance of vaccinations. Also included is a tear-out that can be quickly referenced to help reinforce the information covered in this activity.
Educational Objectives
At the completion of this activity, the participant will be able to:
- Determine the pathology, symptomatology, and diagnosis of respiratory syncytial virus (RSV)
- Explore the latest information on the safety, efficacy, administration, and dosing of the emerging vaccines for RSV
- Examine the role of the pharmacist in the management of RSV, including adult patient education on current preventive methods and emerging vaccines
Activity type: Application
Release date: August 16, 2021
Expiration date: August 16, 2022
Estimated time to complete activity: 2.0 hours
Fee: This lesson is offered for free at www.pharmacytimes.org.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-21-288-H01-P. The activity is available for CE credit through August 16, 2022.Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
The tear out provides a quick reference on RSV to equip pharmacists with a useful tool to help counsel their patients:
Click here to access the Tear Out
Click here to access the Whiteboard animation
Click here to access the Patient Counseling Videos
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Miranda Wilhelm, PharmD
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta
Pharmacy Times® Editorial Staff—Davy James
An anonymous peer reviewer was part of the content validation and conflict resolution and has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
